Newly Driver Mutations Discovered for Medulloblastoma

The study was co-led by researchers at St. Jude Children’s Hospital (Memphis, TN, USA), German Cancer Research Center (Heidelberg, Germany), and Hospital for Sick Children (Toronto, ON, Canada). Whole genome or whole exome sequencing was done on tumor and normal tissue collected from 491 medulloblastoma patients at diagnosis. The team also analyzed DNA methylation and complementary epigenetic data from 1,256 medulloblastoma patients and gene expression data from 392 tumors. The ProteinPaint program was used to help visualize genome data.

“Layering genetic, epigenetic, and transcriptional data, combined with better analytic tools, led to discoveries that would have previously been missed in this highly complex and variable cancer,” said co-first author Paul Northcott, PhD, of St. Jude. Co-author Amar Gajjar, MD, of St. Jude, added: “Using advanced genomic techniques to gain insight into what genetic abnormalities cause medulloblastoma is essential for developing relevant models.”

“Our goal is to understand each patient’s tumor at the molecular level in order to better tailor treatment,” said Dr. Northcott, “This study provides a rich resource for neuro-oncology researchers and clinicians.” It can aid efforts to develop medicines designed to increase survival while reducing treatment-related side effects.

Medulloblastoma is the most common malignant pediatric brain tumor. There are four principal subgroups: WNT, Sonic Hedgehog (SHH), Group 3, and Group 4. The subgroups are driven by different genetic alterations, begin in different cells, and often exhibit different clinical outcomes. About 95% of patients in the WNT subgroup become long-term survivors compared to about 50% for Group 3 patients. There are currently no targeted therapies for Group 3 and Group 4 tumors, which account for over 65% of medulloblastoma cases.

The discoveries include identification of two new suspected oncogenes: KBTBD4 and PRDM6. The genes were found only in Group 3 and Group 4 medulloblastoma and had not previously been associated with any cancer. KBTBD4 was the most frequently mutated gene in those subgroups, involving insertion of one or two amino acids in the same mutation hot spot. The KBTBD4 protein is predicted to function in conjunction with ubiquitin ligase enzymes, but research is underway to better understand how the normal and mutant proteins function.

PRDM6 is an epigenetic regulator of gene activity whose own expression was dramatically increased in 17% of the Group 4 medulloblastoma tumors. If PRDM6 is confirmed to be an oncogene, researchers hope it will lead to development of the first laboratory model of Group 4 medulloblastoma. Such models play a pivotal role in clinical advances.

Overall, the integrated genomic analysis led to identification of altered genes and cellular pathways responsible for over 75% of patients’ tumors. The data also revealed additional complexity within different medulloblastoma subgroups, particularly Group 3 and Group 4. Researchers can access processed study data at no cost through the St. Jude PeCan data portal, the R2: Genomics Analysis and Visualization Platform and the PedcBioPortal for Cancer Genomics.

“The more refined classification of medulloblastoma offered in this study opens avenues for improved risk-stratification of patients and more tailored therapies that target the genomic alterations driving their disease,” said Dr. Gajjar.

The study, by Northcott PA et al, was published July 19, 2017, in the journal Nature.

Related Links:
St. Jude Children’s Hospital
German Cancer Research Center
Hospital for Sick Children